Close Menu

immune repertoire sequencing

Researchers used cell sorting and immune sequencing to uncover an unexpected diversity in T cell response to microbes and vaccines.

NEW YORK (GenomeWeb) — A study using next-generation sequencing to measure changes in T-cell receptor genes of patients treated with anti-CTLA-4 drugs like Bristol-Myers Squibb's Yervoy (ipilimumab) has found that patients whose T-cell landscape changed little from a pre-treatment baseline had im

NEW YORK (GenomeWeb) – CareDx, formerly called XDx, said late Wednesday that it has reached an agreement to acquire transplant diagnostic company ImmuMetrix for an undisclosed amount.

NEW YORK (GenomeWeb News) – Adaptive Biotechnologies today announced it raised $105 million in private funding, which will allow it to expand its immunosequencing research platform and clinical diagnostic products.

NEW YORK (GenomeWeb News) – Adaptive Biotechnologies today said that it has received a $2.53 million Phase II Small Business Innovation Research grant to support its adaptive immune system testing technology.

NEW YORK (GenomeWeb News) – Sequenta has gained the exclusive rights to iRepertoire's IP related to methods of immune cell sequencing for minimal residual disease testing, the two companies said today.

NEW YORK (GenomeWeb News) – A team at the Fred Hutchinson Cancer Research Center has won $4.4 million in funding from the National Cancer Institute to use RNA sequencing to study proteins that may be involved in the body's immune response to cancer, the center said on Monday.

The story has been updated to provide additional details and comments from Adaptive Biotechnologies' CEO, Chad Robins.

NEW YORK (GenomeWeb News) – Adaptive Biotechnologies announced today a deal with Biogen Idec aimed at autoimmune disease biomarkers.

NEW YORK (GenomeWeb News) – Sequenta said today it has received CLIA certification for a clinical test based on in its immune repertoire sequencing-based technology called LymphoSight.

Pages

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.